BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

844 related articles for article (PubMed ID: 19538975)

  • 1. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM; Liang A; Kane SA; Urban MO
    Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CB2 cannabinoid receptor mediation of antinociception.
    Ibrahim MM; Rude ML; Stagg NJ; Mata HP; Lai J; Vanderah TW; Porreca F; Buckley NE; Makriyannis A; Malan TP
    Pain; 2006 May; 122(1-2):36-42. PubMed ID: 16563625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
    Deng L; Cornett BL; Mackie K; Hohmann AG
    Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
    De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
    J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CP55,940 on mechanosensory spinal neurons following chronic inflammation.
    Choong KC; Su X; Urban MO
    Neurosci Lett; 2007 Mar; 414(2):105-9. PubMed ID: 17194542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors.
    Seyrek M; Kahraman S; Deveci MS; Yesilyurt O; Dogrul A
    Eur J Pharmacol; 2010 Dec; 649(1-3):183-94. PubMed ID: 20868676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
    Rao GK; Kaminski NE
    J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.
    Engel MA; Kellermann CA; Burnat G; Hahn EG; Rau T; Konturek PC
    J Physiol Pharmacol; 2010 Feb; 61(1):89-97. PubMed ID: 20228420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain.
    Leánez S; Hervera A; Pol O
    Eur J Pharmacol; 2009 Jan; 602(1):41-9. PubMed ID: 19041302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat.
    Honore P; Donnelly-Roberts D; Namovic MT; Hsieh G; Zhu CZ; Mikusa JP; Hernandez G; Zhong C; Gauvin DM; Chandran P; Harris R; Medrano AP; Carroll W; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1376-85. PubMed ID: 16982702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat.
    Scott DA; Wright CE; Angus JA
    Pain; 2004 May; 109(1-2):124-31. PubMed ID: 15082134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.
    Trotter BW; Nanda KK; Burgey CS; Potteiger CM; Deng JZ; Green AI; Hartnett JC; Kett NR; Wu Z; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2354-8. PubMed ID: 21420860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid CB
    Li AL; Carey LM; Mackie K; Hohmann AG
    J Pharmacol Exp Ther; 2017 Aug; 362(2):296-305. PubMed ID: 28592614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
    Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
    Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous cannabinoid withdrawal produces a differential time-related responsiveness in cannabinoid CB1 receptor gene expression in the mouse brain.
    Oliva JM; Ortiz S; Palomo T; Manzanares J
    J Psychopharmacol; 2004 Mar; 18(1):59-65. PubMed ID: 15107186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages.
    Han KH; Lim S; Ryu J; Lee CW; Kim Y; Kang JH; Kang SS; Ahn YK; Park CS; Kim JJ
    Cardiovasc Res; 2009 Dec; 84(3):378-86. PubMed ID: 19596672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain.
    Furuse S; Kawamata T; Yamamoto J; Niiyama Y; Omote K; Watanabe M; Namiki A
    Anesthesiology; 2009 Jul; 111(1):173-86. PubMed ID: 19512863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity.
    Chuchawankul S; Shima M; Buckley NE; Hartmann CB; McCoy KL
    Int Immunopharmacol; 2004 Feb; 4(2):265-78. PubMed ID: 14996418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis.
    Hasanein P; Shahidi S; Komaki A; Mirazi N
    Eur J Pharmacol; 2008 Sep; 591(1-3):132-5. PubMed ID: 18593578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.